Efficacy, tolerability and acceptability of a novel contraceptive vaginal ring releasing etonogestrel and ethinyl oestradiol

Human Reproduction

Volumn 16, Issue 3, 2001, Pages 469-475

  Roumen, F J M E ^a   Apter, D ^b   Mulders, T M T ^c   Dieben, T O M ^c  

^a Sittard Geleen Heerlen   (Netherlands)

^b Vaestoliitto   (Finland)

^c NV ORGANON   (Netherlands)

Author keywords

Acceptability; Efficacy; Ethinyl oestradiol; Etonogestrel; Vaginal ring

Indexed keywords

ETHINYLESTRADIOL; ETONOGESTREL;

ADULT; ARTICLE; BIOMEDICAL TECHNOLOGY ASSESSMENT; BREAKTHROUGH BLEEDING; CLINICAL TRIAL; CONTROLLED RELEASE FORMULATION; DRUG EFFICACY; DRUG RELEASE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HEADACHE; HORMONAL CONTRACEPTION; HUMAN; LEUKORRHEA; MENSTRUAL CYCLE; MULTICENTER STUDY; NAUSEA; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL; PREGNANCY; SPOTTING; UTERINE CERVIX CYTOLOGY; VAGINA BLEEDING; VAGINA RING; VAGINITIS;

EID: 0035103518     PISSN: 02681161     EISSN: None     Source Type: Journal    
DOI: 10.1093/humrep/16.3.469     Document Type: Article

References (16)

1. A contraceptive vaginal ring releasing norethindrone acetate and ethinyl estradiol
2. A multicenter, uncontrolled clinical investigation of the contraceptive efficacy, cycle control, and safety of a new oral contraceptive containing 20 micrograms ethinyl estradiol and 100 micrograms levonorgestrel over six treatment cycles
3. The influence of different modern low-dose oral contraceptives on intermenstrual bleeding
4. Efficacy and clinical profile of a new oral contraceptive containing norgestimate. U.S. clinical trials
5. A twelve-month comparative clinical investigation of two low-dose oral contraceptives containing 20 micrograms ethinylestradiol/75 micrograms gestodene and 20 micrograms ethinylestradiol/150 micrograms desogestrel, with respect to efficacy, cycle control and tolerance
6. Twelve years of clinical experience with an oral contraceptive containing 30 micrograms ethinyloestradiol and 150 micrograms desogestrel
7. The safety and contraceptive efficacy of a 24-day low-dose oral contraceptive regimen containing gestodene 60 μg and ethinylestradiol 15 μg
8. Cycle control, safety and efficacy of a 24-day regimen of gestodene 60 μg/ethinylestradiol 15 μg and a 21-day regimen of desogestrel 150 μg/ethinylestradiol 20 μg
9. Ovulation inhibition of the novel combined contraceptive vaginal ring NuvaRing
10. Classification and comparison of oral contraceptives containing new generation progestogens
11. Clinical and metabolic effects of gestodene and levonorgestrel
12. The clinical acceptability of a non-medicated vaginal ring
13. The cervico-vaginal epithelium during 20 cycles' use of a combined contraceptive vaginal ring
14. A comparison of the cycle control and tolerability of two ultra low-dose oral contraceptives containing 20 micrograms ethinylestradiol and either 150 micrograms desogestrel or 75 micrograms gestodene
15. Pharmacokinetics of etonogestrel and ethinylestradiol released from a combined contraceptive vaginal ring
16. Efficacy, bleeding patterns, and side effects of a 1-year contraceptive vaginal ring